Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 2.29M shares outstanding
GBAkari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders.
The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes. Nomacopan holds promise for a range of serious conditions, including paroxysmal nocturnal hemoglobinuria (PNH), Guillain-Barré syndrome (GBS), hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and bullous pemphigoid (BP). Akari's operations are headquartered in London, United Kingdom.
Abizer Gaslightwala
Chief Executive Officer, President & Director
Dr. Patel
President and Chief Executive Officer
Dr. Prudo
Chairman of the Board; Director
Hoyoung Huh, M.D.
Chair of the Board
Employees
8
Country
GB
Sector
Healthcare
Website
akaritx.com
Loading congressional disclosures…
based on 2.29M shares outstanding
GB30d Avg
50.01K
60d Avg
75.14K
90d Avg
60.90K
